Literature DB >> 24413321

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells.

Y Zhong1, D El-Gamal1, J A Dubovsky1, K A Beckwith1, B K Harrington2, K E Williams1, V M Goettl1, S Jha1, X Mo3, J A Jones1, J M Flynn1, K J Maddocks1, L A Andritsos1, D McCauley4, S Shacham4, M Kauffman4, J C Byrd5, R Lapalombella1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24413321      PMCID： PMC4013224          DOI： 10.1038/leu.2014.9

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

1.  Normal splenic volumes estimated using three-dimensional ultrasonography.

Authors:  I De Odorico; K A Spaulding; D H Pretorius; A S Lev-Toaff; T B Bailey; T R Nelson
Journal:  J Ultrasound Med       Date:  1999-03       Impact factor: 2.153

2.  Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

Authors:  J A Burger; N Tsukada; M Burger; N J Zvaifler; M Dell'Aquila; T J Kipps
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

3.  Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

Authors:  J A Burger; M Burger; T J Kipps
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

4.  The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.

Authors:  P G Longo; L Laurenti; S Gobessi; A Petlickovski; M Pelosi; P Chiusolo; S Sica; G Leone; D G Efremov
Journal:  Leukemia       Date:  2006-10-05       Impact factor: 11.528

5.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

6.  Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Authors:  Amy J Johnson; David M Lucas; Natarajan Muthusamy; Lisa L Smith; Ryan B Edwards; Michael D De Lay; Carlo M Croce; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

7.  Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB.

Authors:  Liang Yu; Abdalla J Mohamed; Oscar E Simonson; Leonardo Vargas; K Emelie M Blomberg; Bo Björkstrand; H Jose Arteaga; Beston F Nore; C I Edvard Smith
Journal:  Blood       Date:  2008-02-21       Impact factor: 22.113

8.  AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

Authors:  Claudia Haferlach; Cristina Mecucci; Susanne Schnittger; Alexander Kohlmann; Marco Mancini; Antonio Cuneo; Nicoletta Testoni; Giovanna Rege-Cambrin; Antonella Santucci; Marco Vignetti; Paola Fazi; Maria Paola Martelli; Torsten Haferlach; Brunangelo Falini
Journal:  Blood       Date:  2009-05-08       Impact factor: 22.113

9.  Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.

Authors:  Rosa Lapalombella; Bo Yu; Georgia Triantafillou; Qing Liu; Jonathan P Butchar; Gerard Lozanski; Asha Ramanunni; Lisa L Smith; William Blum; Leslie Andritsos; Da-Sheng Wang; Amy Lehman; Ching-Shih Chen; Amy J Johnson; Guido Marcucci; Robert J Lee; L James Lee; Susheela Tridandapani; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2008-09-04       Impact factor: 22.113

10.  Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  S E M Herman; P M Barr; E M McAuley; D Liu; A Wiestner; J W Friedberg
Journal:  Leukemia       Date:  2013-02-06       Impact factor: 11.528
View more
  27 in total

1.  Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Authors:  Zachary A Hing; Rose Mantel; Kyle A Beckwith; Daphne Guinn; Erich Williams; Lisa L Smith; Katie Williams; Amy J Johnson; Amy M Lehman; John C Byrd; Jennifer A Woyach; Rosa Lapalombella
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

Review 2.  Selinexor: First Global Approval.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

3.  Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.

Authors:  A Cosson; E Chapiro; N Bougacha; J Lambert; L Herbi; H-A Cung; C Algrin; B Keren; F Damm; C Gabillaud; M-N Brunelle-Navas; F Davi; H Merle-Béral; M Le Garff-Tavernier; D Roos-Weil; S Choquet; M Uzunov; V Morel; V Leblond; K Maloum; S Lepretre; P Feugier; C Lesty; J Lejeune; L Sutton; Y Landesman; S A Susin; F Nguyen-Khac
Journal:  Leukemia       Date:  2017-03-27       Impact factor: 11.528

Review 4.  Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?

Authors:  Irfana Muqbil; Jack Wu; Amro Aboukameel; Ramzi M Mohammad; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2014-06-17       Impact factor: 15.707

5.  Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.

Authors:  Fabienne Lucas; Kerry A Rogers; Bonnie K Harrington; Rosa Lapalombella; Alexander Pan; Lianbo Yu; Justin Breitbach; Ralf Bundschuh; Virginia M Goettl; Zachary A Hing; Parviz Kanga; Rose Mantel; Deepa Sampath; Lisa L Smith; Ronni Wasmuth; Danielle K White; Pearlly Yan; John C Byrd; Jennifer A Woyach
Journal:  Clin Cancer Res       Date:  2019-07-11       Impact factor: 12.531

6.  PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

Authors:  Dalia El-Gamal; Katie Williams; Taylor D LaFollette; Matthew Cannon; James S Blachly; Yiming Zhong; Jennifer A Woyach; Erich Williams; Farrukh T Awan; Jeffrey Jones; Leslie Andritsos; Kami Maddocks; Chia-Hsien Wu; Ching-Shih Chen; Amy Lehman; Xiaoli Zhang; Rosa Lapalombella; John C Byrd
Journal:  Blood       Date:  2014-07-07       Impact factor: 22.113

7.  BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Authors:  Hatice Gulcin Ozer; Dalia El-Gamal; Ben Powell; Gideon Bollag; John C Byrd; Rosa Lapalombella; Zachary A Hing; James S Blachly; Bonnie Harrington; Shaneice Mitchell; Nicole R Grieselhuber; Katie Williams; Tzung-Huei Lai; Lapo Alinari; Robert A Baiocchi; Lindsey Brinton; Elizabeth Baskin; Matthew Cannon; Larry Beaver; Virginia M Goettl; David M Lucas; Jennifer A Woyach; Deepa Sampath; Amy M Lehman; Lianbo Yu; Jiazhong Zhang; Yan Ma; Ying Zhang; Wayne Spevak; Songyuan Shi; Paul Severson; Rafe Shellooe; Heidi Carias; Garson Tsang; Ken Dong; Todd Ewing; Adhirai Marimuthu; Christina Tantoy; Jason Walters; Laura Sanftner; Hamid Rezaei; Marika Nespi; Bernice Matusow; Gaston Habets; Prabha Ibrahim; Chao Zhang; Ewy A Mathé
Journal:  Cancer Discov       Date:  2018-01-31       Impact factor: 39.397

8.  Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.

Authors:  Michelandrea De Cesare; Denis Cominetti; Valentina Doldi; Alessia Lopergolo; Marcello Deraco; Paolo Gandellini; Sharon Friedlander; Yosef Landesman; Michael G Kauffman; Sharon Shacham; Marzia Pennati; Nadia Zaffaroni
Journal:  Oncotarget       Date:  2015-05-30

9.  Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.

Authors:  Megan N Breit; William C Kisseberth; Misty D Bear; Yosef Landesman; Trinayan Kashyap; Dilara McCauley; Michael G Kauffman; Sharon Shacham; Cheryl A London
Journal:  BMC Vet Res       Date:  2014-07-15       Impact factor: 2.741

10.  Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.

Authors:  Marsha Crochiere; Trinayan Kashyap; Ori Kalid; Sharon Shechter; Boris Klebanov; William Senapedis; Jean-Richard Saint-Martin; Yosef Landesman
Journal:  BMC Cancer       Date:  2015-11-17       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.